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ABSTRACT 
Aberrant DNA methylation seems to be associated with prostate cancer behavior. We investigated 
LINE-1 methylation in prostate cancer and non-neoplastic tissue adjacent to tumor (NTAT) in 
association with mortality from prostate cancer. We selected 157 prostate cancer patients with 
available NTAT from 2 cohorts of patients diagnosed between 1982–1988 and 1993–1996, 
followed up until 2010. An association between LINE-1 hypomethylation and prostate cancer 
mortality in tumor was suggested [hazard ratio per 5% decrease in LINE-1 methylation levels: 1.40, 
95% confidence interval (CI): 0.95–2.01]. After stratification of the patients for Gleason score, the 
association was present only for those with a Gleason score of at least 8. Among these, low (<75%) 
vs. high (>80%) LINE-1 methylation was associated with a hazard ratio of 4.68 (95% CI: 1.03–
21.34). LINE-1 methylation in the NTAT was not associated with prostate cancer mortality. Our 
results are consistent with the hypothesis that tumor tissue global hypomethylation may be a late 
event in prostate cancerogenesis and is associated with tumor progression. 
KEYWORDS: Global hypomethylation, LINE-1, mortality, methylation, non-neoplastic tissue, 
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Abbreviations 
NTAT non-neoplastic tissue adjacent to tumor 
LINE-1 long interspersed nuclear element-1 
PIN prostatic intraepithelial neoplasia 
APC adenomatous polyposis coli 
GSTP1 glutathione S-transferase 1 
TURP transurethral resection of the prostate 
HR hazard ratio 
CI confidence interval 
MAR missing at random 
Introduction 
Prostate cancer is the most common tumor among men worldwide.1 Clinically, it can be an 
aggressive or a latent disease and the clinical behavior of prostate cancer is not entirely explained 
by the tumor's clinical-pathological characteristics. Many molecular markers are being studied in 
association with tumor aggressiveness, especially gene expression profiling2,3 and epigenetic 
changes.4,5 Among the latter markers, aberrant DNA methylation seems to play an important role in 
predicting the tumor behavior.6 
Both gene-specific promoter hypermethylation and global hypomethylation may confer 
aggressiveness to cancer cells.7-9 In prostate cancer, hypermethylation of several genes has been 
associated with tumor aggressiveness in terms of clinical-pathological characteristics, biochemical 
recurrence, and/or mortality from prostate cancer.10-16 Global hypomethylation, which may cause 
reactivation of the transcription of oncogenes and transposable elements and increases 
chromosomal instability and loss of imprinting,17,18 has been less extensively investigated. We have 
recently conducted a systematic review of studies on prostatic tumor global hypomethylation and 
prostate cancer progression:19 although studies were heterogeneous and mostly based on a limited 
sample size, global hypomethylation was reported to be associated with high Gleason score, 
advanced tumor stage, high pre-operative PSA, and presence of metastasis.20-26 
The genome-wide methylation level of the long interspersed nuclear element-1 (LINE-1) is 
considered as a good surrogate marker for global methylation,27-29 as LINE-1 is widely interspersed 
and represents about 15% of human genome.30,31 Thus, in the present study we have analyzed 
prostate tissue LINE-1 methylation status in a cohort of prostate cancer patients in association with 
Gleason score, gene-specific hypermethylation, and mortality from prostate cancer. We analyzed 
both the tumor tissue and the non-neoplastic tissue adjacent to the tumor (NTAT). The study is 
nested in cohorts of prostate cancer patients that we have previously studied to assess the role of 
gene-specific promoter hypermethylation in prostate cancer progression.13,32 
Results 
Selected characteristics of the 157 study patients are reported in Table 1. Most of the patients (82%) 
were diagnosed in the 1990s and the source of tissue was equally distributed among biopsy 
(34.4%), transurethral resection of the prostate (TURP) (34.4%), and radical prostatectomy 
(31.2%). As previously reported,32 among these patients the proportions of promoter methylation of 
glutathione S-transferase 1 (GSTP1) and adenomatous polyposis coli (APC) were higher in tumor 
tissue than in NTAT.  
Tumor tissue LINE-1 methylation 
Analyses were performed in 152 patients, as 5 patients were excluded due to non-detectable LINE-1 
methylation. LINE-1 methylation was higher in TURPs than biopsies and radical prostatectomies 
and was not associated with Gleason score or hypermethylation of APC and GSTP1, although the 
association with gene hypermethylation was, if anything, inverse (Table 2). Results stratified by 
Gleason score showed that an inverse association between LINE-1 hypomethylation and gene-
specific hypermethylation was evident only among patients with a Gleason score of at least 8 
[adjusted coefficient = −2.06, 95% confidence interval (CI): −5.17–1.06] (data not shown).  
There was some evidence of an association between LINE-1 hypomethylation in tumor tissue and 
mortality from prostate cancer, which remained after adjustment for Gleason score and gene-
specific hypermethylation [hazard ratio (HR) per 5% decrease in LINE-1 methylation levels: 1.40, 
95% CI: 0.95–2.01] and was evident also when LINE-1 methylation was treated as a categorical 
variable (Table 3). Analyses on mortality stratified for Gleason score revealed that the association 
between LINE-1 hypomethylation and mortality from prostate cancer was present only in patients 
with a Gleason score of at least 8 (adjusted HR per 5% decrease in LINE-1 methylation levels: 1.76, 
95% CI: 1.00–2.93) (Table 3). In these patients, a low LINE-1 methylation level (< 75%) compared 
with a high methylation level (at least 80%) was associated with a HR of dying from prostate cancer 
of 4.68 (95% CI: 1.03–21.34). We also performed analyses by source of tissue, finding 
homogeneous results among TURPs, radical prostatectomies, and biopsies (Supplementary 
Table 1).  
LINE-1 methylation in non-neoplastic tissue adjacent to the tumor 
As described in the Methods, analyses of LINE-1 methylation in NTAT were restricted to the 105 
patients who underwent a biopsy or a TURP. Consistently with the findings in the tumor tissue, 
LINE-1 methylation in NTAT was higher in TURPs than in biopsies (adjusted coefficient = 3.71, 
95% CI: 1.73- 5.69), while it was not associated with Gleason score or hypermethylation of APC 
and GSTP1 (Table 2). 
As reported in Table 3, LINE-1 methylation in NTAT was not associated with prostate cancer 
mortality (HR per 5% decrease in LINE-1 methylation levels: 0.86, 95% CI: 0.42–1.76). When 
analyses were stratified by source of tumor tissue or Gleason score, all HRs remained close to 1.0 
(Supplementary Table 2). 
Results from a sensitivity analysis restricted to patients with molecular data from newly bisulfite 
modified DNA from NTAT samples were consistent with those obtained from the full sample after 
multiple imputation (Supplementary Tables 3 and 4). 
For 100 patients, we had information on LINE-1 methylation both in the tumor tissue and in the 
NTAT. Although there was no correlation between LINE-1 methylation values of the tumor and the 
NTAT, most of the lowest values were observed in the tumor tissue (Fig. 1). Average methylation 
levels were similar in the two tissues (difference = 0.1%, P = 0.29) but there was no evidence of 
correlation (r = 0.01). No correlation (data not shown) was found either when analyses were 
stratified by source of tumor tissue (TURPs or biopsies).  
Discussion 
We studied LINE-1 methylation status as a marker of global methylation and found that LINE-1 
hypomethylation in the tumor tissue could be associated with mortality from prostate cancer, 
especially in patients with an aggressive disease (i.e., Gleason score of at least 8). These 
associations were not replicated when LINE-1 methylation was analyzed in NTAT. 
In addition, our findings of higher LINE-1 methylation levels in TURPs than in biopsies or radical 
prostatectomies, both in the tumor tissue and in the NTAT, suggest that prostate tumors arising 
from the transition zone could have a different methylation pattern than tumors arising from the 
peripheral zone. This is consistent with data suggesting that tumors of the transition zone, which are 
20–25% of all prostate tumors, show a specific morphological,33 clinical,34,35 biological,36 and 
molecular37-39 behavior. Furthermore, findings of the current study are similar to those of a recent 
study on tumor-negative prostate samplings, in which we found higher LINE-1 methylation levels 
in TURPs than in biopsies.40 
Although our study does not have a large sample size, to our knowledge it is the first to explore the 
relationship between LINE-1 methylation status and mortality from prostate cancer. Furthermore, it 
presented a broad approach, as we analyzed both the tumor tissue and the NTAT and we used 
information on gene-specific hypermethylation. A potential limitation of our study is related to the 
fact that we included heterogeneous sources of tissue (biopsies, TURPs, and radical 
prostatectomies). We have, however, always adjusted for source of tumor tissue in the analyses, as 
well as performed stratified analyses in which we did not find evidence of effect modification of the 
association between LINE-1 methylation and mortality from prostate cancer. Interestingly, lack of 
heterogeneity by source of tissue implies also internal consistency among heterogeneous groups of 
patients, e.g., in regards to the treatment approach, which provides support to the robustness of our 
results. In our study, we did not have information on treatments after the tissue sampling, but it 
should be considered that treatment decisions after the sampling were taken also on the basis of the 
morphological/molecular characteristics of the tumor tissue. Thus, adjustment for post-sampling 
treatments could induce bias rather than control for it. Multifocality of the prostate tumor could 
represent a further critical point, as we did not always had the whole prostate tissue available (e.g., 
in biopsies and TURPs) and, in any case, we analyzed only one randomly chosen block for each 
patient. However, multifocal differences in LINE-1 methylation would likely introduce non-
differential misclassification that is expected, if anything, to underestimate the association between 
LINE-1 methylation and prostate cancer mortality. It is thus reassuring that we found a stronger 
association for the tumor tissue, in which multifocality is an issue, than for the NTAT. Finally, we 
had to use multiple imputation to include cases whose DNA could not be newly modified. This 
method imputes missing data while acknowledging the uncertainty associated with the imputed 
values and provides valid statistical inferences under the missing at random (MAR) 
assumption.41,42,43 Indeed, when data are MAR, analyses based on complete cases may be biased 
because cases with missing values may differ systematically from the completely observed cases. In 
our study, results obtained using multiple imputations or a complete case approach were similar. 
Our data suggest increased mortality from prostate cancer associated with lower levels of LINE-1 
methylation in the tumor tissue. It has been suggested that global hypomethylation is a late 
epigenetic mechanism that could play a role in progression of advanced prostate cancer.24 
Moreover, it has been suggested that a high de-repression, via hypomethylation, of LINE-1 
promoter could induce a general dysregulation that involves chromosomal instability, reactivation 
of repeated sequences, and oncogenes.24,22 Our results are consistent with these suggestions, as the 
association between LINE-1 hypomethylation and mortality from prostate cancer was limited to 
men with an aggressive tumor (Gleason score 8+). On the other hand, there was no association 
between LINE-1 methylation and Gleason score. Although this latter finding is not completely 
inconsistent with previous studies (a clear association between LINE-1 hypomethylation and 
Gleason score has been found only in one out of 3 previous studies22,23,26), if global methylation was 
a late event in prostate cancerogenesis, we would have expected higher hypomethylation among 
patients with a Gleason score of at least 8. It could be speculated that global methylation is more 
related to the metastatic potential of aggressive prostate cancers than to the Gleason score, and it is 
of interest that previous studies strongly indicate a decreased global methylation in the prostate 
cancer tissue among prostate cancer patients with systemic metastases.21,24 In addition, some studies 
have found widespread genome-wide hypomethylation as well as focal hypermethylation in prostate 
cancer metastases from different sites (e.g., bone, liver). These studies confirm that the 
hypomethylation in metastasis showed a pattern that induces genetic instability rather than the 
regulation of specific genes. Hypermethylation at specific genes is less common but strongly 
maintained among different metastasis from a patient.44,45 
Gene-specific hypermethylation and global hypomethylation are often considered to coexist in the 
process of carcinogenesis.7,9,17 We did not find clear evidence of an association of LINE-1 
hypomethylation with GSTP1 and APC hypermethylation, although the inverse association became 
stronger in more advanced tumors. These data give some support to (or at least do not contradict) 
the concept of an “epigenetic catastrophe”46,9 occurring with prostate tumor development and 
progression. 
In a previous study, based on the same patients included in the current study, we found that 
hypermethylation in APC and GSTP1 in the NTAT was associated with a strongly increased risk of 
dying from prostate cancer.32 Those results supported the concept of field cancerization, i.e., that 
molecular dysregulations may occur in the NTAT before the tumor becomes morphologically 
evident. Our current null results on LINE-1 methylation in NTAT do not provide further support to 
the concept of field cancerization; however, they are consistent with the hypothesis that global 
hypomethylation is a late event in cancerogenesis that, accordingly, would not be detectable in 
NTAT. 
In conclusion, our data suggest that global hypomethylation may be a late event in cancerogenesis 
that is associated with tumor progression and mortality for tumors with high Gleason score. 
Materials and methods 
Patients and samples 
The study is nested in 2 cohorts of, in total, 459 patients with prostate cancer diagnosed between 
1982–1988 (1980s cohort) and 1993–1996 (1990s cohort) at the San Giovanni Battista Hospital of 
the city of Turin, Italy. These patients were followed up for cause-specific mortality until August 
2010. A detailed description of the 2 cohorts has been published previously.13 Briefly, for all 459 
patients we collected demographic and clinical information (age, residence, source of prostatic 
tumor tissue-biopsy, radical prostatectomy or transurethral resection of the prostate, and tumor 
grade) from the pathology reports and traced the corresponding blocks of formalin fixed tumor 
tissue. All diagnostic slides were traced and reviewed by an uropathologist to assign a uniform 
Gleason score. In addition, as previously described,32 diagnostic slides were analyzed to identify 
areas of (NTAT). We identified a subcohort of 157 patients with NTAT relying on restrictive 
criteria, including absence of areas of prostatic intraepithelial neoplasia (PIN), availability of tissue 
(all biopsies from the 1980s cohort were a priori excluded as areas of NTAT that were too limited) 
and possibility to identify an area of NTAT. If more than one area of NTAT was present, the 
farthest area from the tumor was chosen. The portions of NTAT collected had at least 1.5 mm of 
distance from tumor cells. The selected NTAT were manually dissected from slices overlapping the 
area highlighted from the uropathologist. 
The current study is conducted in this cohort of 157 patients, for whom we potentially had access on 
both the tumor tissue and the NTAT. From previous studies we had qualitative information on 
promoter hypermethylation of adenomatous polyposis coli (APC) and glutathione S-transferase 1 
(GSTP1) in the tumor tissue and in the NTAT.13,32 We also had stored (at −20°C) DNA extracted 
from the tumor tissue (for all patients) and from NTAT (for 91 patients) as well as stored (at -80°C) 
bisulfite-modified DNA from NTAT (for 49 patients). For 17 patients, stored DNA (modified or 
not) from NTAT was not available. 
The study was approved by the Ethical Committee of the San Giovanni Battista Hospital - 
CTO/CRF/Maria Adelaide Hospital of Turin. 
Molecular analysis 
Available stored genomic DNA from the 157 tumor tissue samples and from the 91 NTAT samples 
(248 samples in total for 157 patients) underwent bisulfite modification using the Epitect Bisulfite 
Kit (Qiagen, Hilden, Germany). Controls fully methylated and unmethylated (CpGenomeTM 
universal methylated DNA and CpGenomeTM universal unmethylated DNA, Chemicon Co. 
Billerica, MA) were included in the modification set. We conducted molecular analyses on LINE- 1 
methylation both on these 248 newly modified samples and on the 49 stored bisulfite-modified 
DNA samples. 
LINE-1 (GenBank accession number X58075) promoter methylation was analyzed using PyroMark 
Q24 MDx (Qiagen). Primers (forward 5′-TTTGAGTTAGGTGTGGGATATAGTT-3′, reverse 5′-
Biot-CACCTAAAAAATCCAATCACTCC-3′ and sequencing 5′-
TTAGGTGTGGGATATAGTTT-3′), not covering CpG sites, produce a 98 bp amplicon containing 
3 CpG sites (positions 819, 826, and 829) and were designed according to PyroMark Assay Design 
software version 2.0 (Qiagen). We performed PCR reaction in a total volume of 35 µl containing 
1X buffer (KCl), 2 mM MgCl2, 0.8 mM dNTPs, 0.5 µM of each primer, 0.05 U Taq polymerase 
and 6 µl of bisulfite-modified DNA with the following cycling profile: 95°C for 10 min followed by 
45 cycles of denaturation at 95°C for 30 sec, annealing at 55°C for 1 min, extension at 72°C for 
1 min and final extension at 72°C for 10 min. The sequence to analyze was 
C/TGTGGTGC/TGTC/TG and the dispensation order was GTCGTAGATAGTCAGATC. Positive 
controls for methylated and unmethylated status were included in each pyrosequencing run. 
Methylation quantification was expressed for each CpG site selected as percentage of methylated 
cytosine divided by the sum of methylated and unmethylated cytosine. 
Statistical analysis 
As measure of LINE-1 methylation status, we calculated the mean methylation levels of the 3 CpG 
sites analyzed in the LINE-1 promoter (all pairways correlation coefficients were >0.83). LINE-1 
methylation was treated as a continuous variable, but we also created a categorical variable using 3 
levels of methylation: <75%, 75–79.9%, and ≥80%. 
LINE-1 methylation in the tumor tissue 
We used multivariable linear regression to estimate the association between selected characteristics 
(age, year of diagnosis, source of tumor tissue, Gleason score, and tumor tissue methylation in APC 
and GSTP1) and level of LINE-1 methylation in the tumor tissue. Normality was satisfied as 
indicated by tests based on skewness and kurtosis (P>0.15). 
We used a Cox proportional hazard regression model to estimate the hazard ratio (HR) of mortality 
from prostate cancer in association with LINE-1 methylation in the tumor tissue. Time from 
diagnosis was used as the time axis, while age and year of diagnosis were introduced as continuous 
variables. The proportional hazard assumption was met as indicated by a test based on Schoenfeld 
residuals (P = 0.34). Models were always adjusted for the source of tumor tissue and progressively 
adjusted for tumor tissue methylation in APC and GSTP1 and Gleason score (variables categorized 
as shown in Table 1). We adjusted for gene-specific methylation as it has been suggested that global 
hypomethylation may coexist with gene-specific hypermethylation, and the latter has been 
associated with mortality from prostate cancer.13 Additional analyses were performed stratifying by 
source of tumor tissue and Gleason score (<8, ≥8). 
LINE-1 methylation in the NTAT 
Analyses of LINE-1 methylation in NTAT were restricted to biopsies and transurethral resections of 
the prostate (TURPs) (105 patients out of 157). Through the preliminary results of this study and 
the results of a parallel study of our group,40 we found that the distinction between transition and 
peripheral zone of prostate was important as these two tissues have strong differences in LINE-1 
methylation levels. In our study, the NTAT was sampled without considering whether it came from 
the peripheral or the transition zone. To identify a posteriori the tissue of origin (i.e., peripheral or 
transition) of the NTAT samples obtained from the radical prostatectomies, we reviewed the slides 
selected for the DNA extraction: in most of the cases (30) the tissue was of a mixed nature, while 
we could identify a clear peripheral origin for 9 cases and a clear transition origin for 10 cases. 
When we analyzed LINE-1 methylation in these 3 groups, we found a mean LINE-1 methylation of 
77.8% in the peripheral tissues, 78.8% in the mixed tissues, and 79.5% in the transition tissues, thus 
further supporting the notion that the transition tissue has a higher methylation compared with the 
peripheral tissue. These patients were however excluded from the mortality analyses as NTAT of 
mixed origin could bias the estimates, while there were too few events among the other 2 groups (2 
events among patients with NTAT of peripheral origin and 1 event among patients with NTAT of 
transition origin) to be added to the analyses. 
Since the long-time storage of bisulfite-modified DNA could alter the molecular results and data on 
LINE-1 methylation level in NTAT from newly modified DNA were available only for 52 patients 
(48% of the 105 patients with a TURP or a biopsy), we performed multiple imputation to obtain 
complete and more valid information on LINE-1 methylation for all 105 patients. Specifically, a 
multivariate imputation by chained equations (MICE) approach was adopted assuming the data 
were missing at random (MAR).47,48 The imputation model involved regression of the LINE-1 
methylation level in the NTAT measured on the newly modified DNA on: year of diagnosis, age at 
diagnosis, source of tissue, Gleason score, number of methylated genes out of APC and GSTP1 in 
the tumor tissue and in NTAT, LINE-1 tumor methylation level, LINE-1 NTAT methylation level 
measured on the stored modified DNA, and survival data, including the event indicator, the 
cumulative hazard at the time of entry for the event actually experienced, and the difference 
between the estimated cumulative hazard at the exit time and that at entry.49 After fitting the 
imputation model, imputed values for the missing data were created using predictive mean 
matching. 
For each imputed data set (n = 20) we performed a multivariable linear regression to estimate the 
association between selected characteristics and level of LINE-1 methylation in NTAT and a Cox 
regression to estimate the HR of mortality from prostate cancer for NTAT LINE-1 methylation. 
Analyses stratified by Gleason score (<8, ≥8) were also conducted. Estimates obtained in each data 
set were then combined into overall estimates, with standard errors, confidence intervals and P-
values calculated using Rubin's rule.50 
We also compared the mean LINE-1 global methylation levels between the NTAT and the tumor 
tissue, using the Wilcoxon test for paired data and estimating the Spearman correlation coefficient. 
This analysis was further stratified by source of tumor tissue (TURP or biopsy). 
As a sensitivity analysis, we repeated the analyses on LINE-1 methylation status in the NTAT 
restricting to patients for whom newly modified DNA was available (n = 52). 
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